Swearing, shouting and spitting: Lundbeck and Otsuka market new Rexulti indication in ad

Lundbeck and its Japanese partner Otsuka announce a new treatment option for agitation in Alzheimer’s patients in a TV commercial.

by ANDREAS LØNSTRUP

Back in May, Lundbeck and Otsuka received approval from the US Food and Drug Administration (FDA) to bring schizophrenia drug Rexulti to the market for the treatment of Alzheimer’s patients with agitation.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

Access all locked articles

Receive our daily newsletters

Access our app

Get full access for you and your coworkers

Start a free company trial today

Lilly applies for Alzheimer’s drug’s US approval after trial success
For subscribers
New Alzheimer’s drug is first to show it slows disease – but it’s facing a rocky rollout
For subscribers

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Adam Steensberg, CEO, Zealand Pharma | Foto: Stine Bidstrup

Pharma & biotech

Zealand sells USD 1 billion in shares to fund new obesity drugs

Zealand’s shares have climbed 138 percent this year.

For subscribers

Pharma & biotech

Novo Nordisk CEO to testify before senate committee in September

For subscribers

Pharma & biotech

UK court gives NHS green light to claim damages against Lundbeck

For subscribers

Albert Bourla, CEO of Pfizer, announced on Monday that the company is testing three potential weight loss drugs.

Pharma & biotech

Pfizer is testing three new weight loss candidates

For subscribers

Pharma & biotech

Teva to launch generic copy of Novo Nordisk drug in the US

Pharma & biotech

FDA accepts Lundbeck's application for Rexulti as supplementary PTSD treatment

Zealand Pharma is very open to partnership after promising obesity data
The company’s weight-loss drug Petrelintid has just delivered positive results.
Novo Nordisk sets new record as market value surpasses USD 650bn
Each share in Novo Nordisk now costs over USD 145.
Eli Lilly appoints Nordic Head of Public Affairs
He comes from a position as government affairs director in the Nordics for Vertex Pharmaceuticals and has previously also worked for Novo Nordisk.
For subscribers
Wegovy approved in China
Novo Nordisk’s weight loss drug Wegovy has been approved for the treatment of severe obesity in China.
Novo Nordisk announces USD 4.1bn factory expansion in North Carolina
After months of speculation, Novo Nordisk has formally announced its plans to expand production facilities in Clayton.
Underdog obesity drug performs well in Phase II study
Altimmune has shown that the company’s weight loss drug pemvidutid predominantly provides weight loss from lost fat mass, rather than muscle.
For subscribers

Pfizer is testing three new weight loss candidates

Two of the experimental drugs are GLP-1 agents.

For subscribers

Pharma & biotech

UK court gives NHS green light to claim damages against Lundbeck

Although it is more than ten years since the European Commission ruled that Lundbeck entered into illegal pay-for-delay agreements regarding the drug Citalopram, the NHS can still claim compensation.

For subscribers

Pharma & biotech